Why Zymeworks Inc.’s (ZYME) Stock Is Down 5.26%
As of Friday, July 10, Zymeworks Inc.’s ZYME share price has dipped by 5.26%, which has investors questioning if this is right time to buy.Jenna Brashear
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company’s platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Commentary & Analysis
Why Zymeworks Inc.’s (ZYME) Stock Is Up 7.93%
As of Tuesday, June 30, Zymeworks Inc.’s ZYME share price has surged by 7.93%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Zymeworks Inc.’s (ZYME) Stock Is Down 7.56%
As of Monday, June 29, Zymeworks Inc.’s ZYME share price has dipped by 7.56%, which has investors questioning if this is right time to buy.Jenna Brashear
Why Zymeworks Inc.’s (ZYME) Stock Is Down 6.43%
As of Friday, May 08, Zymeworks Inc.’s ZYME share price has dipped by 6.43%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why Zymeworks Inc.’s (ZYME) Stock Is Down 11.33%
As of Friday, May 08, Zymeworks Inc.’s ZYME share price has dipped by 11.33%, which has investors questioning if this is right time to buy.Tudor Pop
Financial Summary
| Share Statistics | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,570.6 | $252.6 | 51% |
|
| Shares Out (Mil) | 74.7 | 52.3 | 57% |
|
| Institutional Ownership | 97.3% | 92.1% | 73% |
|
| Float (Mil) | 66.7 | 40.2 | 54% |
|
| Beta | 1.19 | 0.95 | 70% |
|
| Avg Daily Volume (000s) | 370 | 455 | 54% |
|
| Price Change (52-week) |
69.6% | 52.9% | 86% |
|
| Growth | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 22.1% | 13.6% | 84% |
|
| Net Income (5yr) | 14.8% | (9.9%) | 62% |
|
| EPS (5yr) | 21.4% | 16.0% | 70 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.5%) | (15.6%) | 43% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 9 | 7 | 5 | |
| Current EPS | ($0.549) | $1.237 | $0.828 | |
| Month Ago EPS | ($0.407) | $1.399 | $0.322 | |
| # Rev Up | 1 | 2 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.189) | $1.226 | $0.787 | |
| Year/Year Chg | (7.3%) | (214.7%) | (72.2%) | |
| Financials | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $81 | $38 | 24% |
|
| Net Income (TTM) (Mil) | ($103) | ($43) | 10% |
|
| EPS (TTM) | ($1.364) | ($1.600) | 18% |
|
| Operating Cash Flow (TTM) (Mil) | ($75) | ($31) | 7% |
|
| Net Cash Flow (TTM) (Mil) | $168 | $5 | 83% |
|
| Long-Term Debt (Q1) (Mil) | $14 | $5 | 30% |
|
| Enterprise Value (Q1) (Mil) | $1,358 | $180 | 45% |
|
| Valuation | ZYME | Industry Median |
Percentile (All Stocks) |
|
| P/B | 10.02 | 2.56 | 90% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | ZYME | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | (67.0%) | 63.8% | 2% |
|
| Net Margin | (126.3%) | (67.3%) | 6% |
|
| ROA | (22.7%) | (49.8%) | 19% |
|
| ROE | (42.0%) | (55.5%) | 17% |
|
| Liabilities to Assets | 65.8% | 30.3% | 61% |
|
| F-Score | 4 | 3 | 34% |
|
Zymeworks Inc. did not pass any screens on 7/31/2026.
